A recent study demonstrated that tipifarnib, a farnesyltransferase inhibitor that disrupts HRAS function, dramatically improved clinical outcomes in patients with HRAS-mutant HNSCC [21]. This evidence concerns the gene HRAS and head and neck squamous cell carcinoma.